Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York, NY. 

Steve Lundy, President and CEO of Venaxis™, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:Piper Jaffray 25th Annual Healthcare ConferenceDate:Tuesday, December 3, 2013 Time:9:30 am (Eastern Time) Location: 

The New York Palace Hotel, New York, NY The presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast will be archived and available for 90 days.

Separately, Venaxis is scheduled to ring The NASDAQ Stock Market Closing Bell on December 6, 2013 in a ceremony to celebrate the company's recent achievements as it advances the APPY1 Test toward potential FDA clearance and expands its commercial footprint in the EU.  Venaxis remains on track to complete patient enrollment for its pivotal clinical study of the APPY1 Test in the United States at or around the end of 2013.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda
csojda@tiberend.com; (212) 375-2686


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):